OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)
South Korea · Delayed Price · Currency is KRW 6,080.00
+80.00 (1.33%)
At close: Aug 14, 2026
OPTUS Pharmaceutical Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 91,625 | 87,161 | 81,905 | 72,426 | 58,658 | 57,316 |
Revenue Growth | 11.80% | 6.42% | 13.09% | 23.47% | 2.34% | -5.77% |
Gross Profit Gross Profit Growth | 50,752 | 48,125 | 44,628 | 41,354 | 31,617 | 32,495 |
Operating Income Operating Income Growth | 10,859 | 8,875 | 8,509 | 8,187 | 5,249 | 10,472 |
Net Income Net Income Growth | 12,696 | 11,358 | 10,308 | 10,760 | 5,012 | 9,892 |
Earnings Per Share EPS Growth | 796.25 | 730.00 | 675.00 | 708.00 | 316.00 | 617.00 |
EPS Growth | 33.91% | 8.15% | -4.66% | 124.05% | -48.78% | -30.91% |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Tearin Blood and Others Tearin Blood and Others Growth | 77,761 | 69,708 | 56,535 | - | 58,799 |
Nexol Tablet and Others Nexol Tablet and Others Growth | 2,938 | 2,159 | 1,786 | - | 1,496 |
LDPE Scrap and Others LDPE Scrap and Others Growth | 710 | 356 | - | 306.36 | - |
Oesu Eye Cleaner and Others Oesu Eye Cleaner and Others Growth | 496 | 203 | - | - | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 34,704 | 39,796 | 51,408 | 68,522 | 61,555 | 74,555 |
Total Debt Total Debt Growth | 1,378 | 972.44 | 1,454 | 2,073 | 2,598 | 240.2 |
Net Cash (Debt) Net Cash Growth | 33,326 | 38,824 | 49,955 | 66,450 | 58,956 | 74,315 |
Net Cash Growth | -17.36% | -22.28% | -24.82% | 12.71% | -20.67% | -9.30% |
Net Cash Per Share Net Cash Per Share Growth | 2091.96 | 2497.73 | 3271.06 | 4372.19 | 3717.14 | 4635.53 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 13,315 | 16,225 | 8,905 | 12,438 | 2,045 | 7,071 |
Capital Expenditures CapEx Growth | -50,084 | -44,515 | -11,808 | -3,329 | -6,001 | -10,628 |
Free Cash Flow Free Cash Flow Growth | -36,768 | -28,290 | -2,903 | 9,109 | -3,955 | -3,557 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 55.39% | 55.21% | 54.49% | 57.10% | 53.90% | 56.69% |
Operating Margin | 11.85% | 10.18% | 10.39% | 11.30% | 8.95% | 18.27% |
Pretax Margin | 13.98% | 12.68% | 14.75% | 17.91% | 11.64% | 18.28% |
Profit Margin | 13.86% | 13.03% | 12.59% | 14.86% | 8.54% | 17.26% |
FCF Margin | -40.13% | -32.46% | -3.55% | 12.58% | -6.74% | -6.21% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 7.64 | 10.69 | 9.56 | 7.99 | 20.27 | 11.34 |
P/FCF Ratio | - | - | - | 9.43 | - | - |
PS Ratio | 1.17 | 1.39 | 1.20 | 1.19 | 1.73 | 1.96 |